JPWO2022036151A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022036151A5 JPWO2022036151A5 JP2023509698A JP2023509698A JPWO2022036151A5 JP WO2022036151 A5 JPWO2022036151 A5 JP WO2022036151A5 JP 2023509698 A JP2023509698 A JP 2023509698A JP 2023509698 A JP2023509698 A JP 2023509698A JP WO2022036151 A5 JPWO2022036151 A5 JP WO2022036151A5
- Authority
- JP
- Japan
- Prior art keywords
- weighing
- dose
- day
- patients weighing
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025204019A JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063065107P | 2020-08-13 | 2020-08-13 | |
| US63/065,107 | 2020-08-13 | ||
| PCT/US2021/045823 WO2022036151A1 (en) | 2020-08-13 | 2021-08-12 | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204019A Division JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023539047A JP2023539047A (ja) | 2023-09-13 |
| JP2023539047A5 JP2023539047A5 (https=) | 2024-08-22 |
| JPWO2022036151A5 true JPWO2022036151A5 (https=) | 2024-08-22 |
| JP7821160B2 JP7821160B2 (ja) | 2026-02-26 |
Family
ID=77655658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509698A Active JP7821160B2 (ja) | 2020-08-13 | 2021-08-12 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
| JP2025204019A Pending JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204019A Pending JP2026026191A (ja) | 2020-08-13 | 2025-11-26 | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240209071A1 (https=) |
| EP (1) | EP4196161A1 (https=) |
| JP (2) | JP7821160B2 (https=) |
| KR (1) | KR20230047179A (https=) |
| CN (1) | CN116249550A (https=) |
| AU (1) | AU2021326526B2 (https=) |
| CA (1) | CA3173007A1 (https=) |
| IL (1) | IL300115A (https=) |
| MX (1) | MX2023001702A (https=) |
| WO (1) | WO2022036151A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120035450A (zh) | 2022-09-06 | 2025-05-23 | 阿雷克森制药公司 | 造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱 |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6654137B2 (ja) * | 2013-09-16 | 2020-02-26 | チルドレンズ ホスピタル メディカル センター | Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| JP2019517473A (ja) * | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| JP2023522208A (ja) * | 2020-04-16 | 2023-05-29 | アシスタンス ピュブリック－オピト ド パリ | ウイルスによって引き起こされる補体媒介性障害を処置する方法 |
-
2021
- 2021-08-12 IL IL300115A patent/IL300115A/en unknown
- 2021-08-12 US US18/018,936 patent/US20240209071A1/en active Pending
- 2021-08-12 KR KR1020237008325A patent/KR20230047179A/ko active Pending
- 2021-08-12 JP JP2023509698A patent/JP7821160B2/ja active Active
- 2021-08-12 CA CA3173007A patent/CA3173007A1/en active Pending
- 2021-08-12 MX MX2023001702A patent/MX2023001702A/es unknown
- 2021-08-12 WO PCT/US2021/045823 patent/WO2022036151A1/en not_active Ceased
- 2021-08-12 AU AU2021326526A patent/AU2021326526B2/en active Active
- 2021-08-12 CN CN202180050198.2A patent/CN116249550A/zh active Pending
- 2021-08-12 EP EP21766299.8A patent/EP4196161A1/en active Pending
-
2025
- 2025-11-26 JP JP2025204019A patent/JP2026026191A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526534A5 (https=) | ||
| Waxman et al. | Complement depletion accelerates the clearance of immune complexes from the circulation of primates. | |
| JP7101621B2 (ja) | 単一ドメイン血清アルブミン結合タンパク質 | |
| JP7463070B2 (ja) | バイオ医薬組成物 | |
| CN107001459B (zh) | 用于治疗炎症和自身免疫紊乱的抗age抗体 | |
| US8784822B2 (en) | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis | |
| US9243060B2 (en) | Humanized anti-factor C3b antibodies and uses thereof | |
| JP2020528894A5 (https=) | ||
| JP2024096868A (ja) | 可溶性補体受容体１型変異体及びそれらの使用 | |
| CN108409863B (zh) | 抗凝血因子xi抗体 | |
| JP2021525718A5 (https=) | ||
| JP7788281B2 (ja) | 可溶性補体受容体１型変異体コンジュゲートおよびその使用 | |
| JPWO2018191479A5 (https=) | ||
| CN119452255A (zh) | 用于治疗肾脏疾病或障碍的方法 | |
| JP4339405B2 (ja) | 予防・治療剤 | |
| EP4442273A1 (en) | Method for preventing and/or treating thromboembolic diseases | |
| JPWO2020154626A5 (https=) | ||
| JPWO2022036151A5 (https=) | ||
| JPWO2019231983A5 (https=) | ||
| JPWO2022011086A5 (https=) | ||
| WO1999024069A1 (fr) | Medicaments preventifs et therapeutiques pour des affections pulmonaires diffuses | |
| TWI886758B (zh) | 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途 | |
| RU2021125057A (ru) | ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС) | |
| JP4599028B2 (ja) | 新規な炎症性疾患改善剤 | |
| WO1998017312A1 (en) | Sepsis remedy comprising anti-il-8 antibody as active ingredient |